Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells.
These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Keywords: AIDS; CD4-MHC II; Camelids; Cell-mediated virus inhibition; Chondrichthyes; Conjugating Antibodies; Efalizumab; HIV; Half Life; Human Genome Sciences; Ibalizumab; Natalizumab; PEGylation; Passive immunization; Therapeutic Antibodies; anti-HIV drug; antiretroviral therapy; autoimmune diseases; calicheamicin; cancers; cellular-phagocytosis; complement-mediated cytotoxicity; duocarmycin; gp120; gp41; immunotoxin; infectious diseases; neutralizing antibodies; palivizumab; passive immunization; polyclonal immunoglobulin; prophylaxis; respiratory syncytial virus; simian immunodeficiency virus-HIV chimera; therapeutic antibodies; viral infections
Document Type: Research Article
Publication date: November 1, 2010
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites